Tonix Pharmaceuticals Holding Stock Alpha and Beta Analysis
| TNXP Stock | USD 0.19 0.01 5.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Tonix Pharmaceuticals Holding. It also helps investors analyze the systematic and unsystematic risks associated with investing in Tonix Pharmaceuticals over a specified time horizon. Remember, high Tonix Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Tonix Pharmaceuticals' market risk premium analysis include:
Beta 3.49 | Alpha (1.10) | Risk 7.98 | Sharpe Ratio (0.02) | Expected Return (0.18) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Tonix |
Tonix Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Tonix Pharmaceuticals market risk premium is the additional return an investor will receive from holding Tonix Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Tonix Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Tonix Pharmaceuticals' performance over market.| α | -1.1 | β | 3.49 |
Tonix Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Tonix Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Tonix Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Tonix Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Tonix Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Tonix Pharmaceuticals shares will generate the highest return on investment. By understating and applying Tonix Pharmaceuticals stock market price indicators, traders can identify Tonix Pharmaceuticals position entry and exit signals to maximize returns.
Tonix Pharmaceuticals Return and Market Media
The median price of Tonix Pharmaceuticals for the period between Thu, Aug 29, 2024 and Wed, Nov 27, 2024 is 0.15 with a coefficient of variation of 28.09. The daily time series for the period is distributed with a sample standard deviation of 0.05, arithmetic mean of 0.17, and mean deviation of 0.03. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Bavarian Nordic stock slides on Moderna mpox vaccine study | 09/05/2024 |
2 | Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace SymTouch to Treat Migraines | 09/27/2024 |
3 | Tonix Pharmaceuticals announces submission of NDA for non-opioid analgesic | 10/16/2024 |
4 | Can Tonixs Antivirals Boost Military Defense | 10/17/2024 |
5 | Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe 2024 | 10/24/2024 |
6 | Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024 | 11/01/2024 |
7 | Tonix Pharmaceuticals GAAP EPS of -0.23 beats by 3.65, revenue of 2.82M misses by 0.33M | 11/12/2024 |
8 | Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Companys Single-Dose Mpox and Smallpox Vaccine Can... | 11/13/2024 |
9 | Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments | 11/14/2024 |
10 | Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology Convergence 2024 Annua... | 11/18/2024 |
11 | Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference | 11/26/2024 |
About Tonix Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Tonix or other stocks. Alpha measures the amount that position in Tonix Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2010 | 2023 | 2024 (projected) | Dividend Yield | 0.007063 | 0.42 | 0.44 | Price To Sales Ratio | 0.88 | 0.8 | 0.7 |
Tonix Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Tonix Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Tonix Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Tonix Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Tonix Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Tonix Pharmaceuticals' management manipulating its earnings.
| 11th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 11th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Tonix Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Tonix Stock Analysis
When running Tonix Pharmaceuticals' price analysis, check to measure Tonix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tonix Pharmaceuticals is operating at the current time. Most of Tonix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tonix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tonix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tonix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.